CGTLive’s Weekly Rewind – April 15, 2022
Review top news and interview highlights from the week ending April 15, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. GD2-CAR T-Cell Therapy Yields Clinical Benefit in Glioma
While the lower IV dose was generally well-tolerated, the higher dose yielded cases of serious cytokine release syndrome.
2. Liso-Cel Approved for R/R B-Cell Lymphoma by European Commission
The decision was based on findings from the phase 1 TRANSCEND NHL 001 clinical trial.
3. Combination CAR T-Cell Therapy, RNA Vaccine Shows Efficacy in Solid Tumors
The novel regimen from BioNTech demonstrated encouraging results in patients with testicular or ovarian cancer.
4. Cord Blood Combined Natural Killer Cell Engager Therapy Shows Efficacy in Lymphoma
AFM13 is currently also being evaluated on its own in lymphoma in a phase 2 registrational study.
5. FBX-101 and the RESKUE Trial: Exploring AAV-Based Gene Therapies for Krabbe Disease
Erandi De Silva, PhD, co-founder and senior vice president of product development at Forge Biologics, discusses the dual approach of her company in manufacturing and also developing adeno-associated viral-based gene therapies, including FBX-101 for Krabbe disease.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
